Advertisement

Jak/STAT Signaling in HNC

  • Bhavana S. Vangara
  • Jennifer R. Grandis
Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

The Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway relays signals from cytokine receptors and receptor tyrosine kinases to the nucleus, thereby altering the expression of genes regulating normal cell functions, including growth, differentiation, and apoptosis. Constitutive Jak/STAT activation has been detected in most epithelial malignancies including head and neck cancer (HNC). STAT3 activation in HNC alters cell cycle progression, inhibits apoptosis, and facilitates proliferation and survival of cancer cells. Inhibition of aberrant STAT3 by a variety of strategies has been shown to abrogate HNC growth in vitro and in vivo suggesting that clinical approaches to block STAT3 activation may be beneficial in this cancer. Understanding the consequences of Jak/STAT pathway mutation is integral to developing and improving targeted therapies for HNC. In this chapter, we will review Jak and STAT inhibitors presently under development in preclinical models as well as treatments further along the pipeline that have entered clinical investigation.

Keywords

Head and neck cancer Squamous cell carcinoma Jak STAT Targeted therapies 

References

  1. 1.
    Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol–Head Neck Surg. 2011;137(5):499–507. doi:10.1001/archoto.2011.63.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2012. doi:10.1016/j.oraloncology.2012.06.006.Google Scholar
  3. 3.
    Arany I, Chen SH, Megyesi JK, Adler-Storthz K, Chen Z, Rajaraman S, Ember IA, Tyring SK, Brysk MM. Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett. 2003;199(1):83–89.PubMedCrossRefGoogle Scholar
  4. 4.
    Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J: Off Publ FedAm Soc Exp Biol. 2006;20(12):2093–2101. doi:10.1096/fj.06-6191com.CrossRefGoogle Scholar
  5. 5.
    Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Target. 2006;6(8):691–710.CrossRefGoogle Scholar
  6. 6.
    Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 1998;394(6689):145–51. doi:10.1038/28101.PubMedCrossRefGoogle Scholar
  7. 7.
    Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28. doi:10.1016/S1470-2045(09)70311-0.PubMedCrossRefGoogle Scholar
  8. 8.
    Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem. 2003;278(39):37610–21. doi:10.1074/jbc.M301629200.PubMedCrossRefGoogle Scholar
  9. 9.
    Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003;197(2):157–168. doi:10.1002/jcp.10364.PubMedCrossRefGoogle Scholar
  10. 10.
    Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996;272(5262):719–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci. 2008;33(3):122–131. doi:10.1016/j.tibs.2007.12.002.PubMedCrossRefGoogle Scholar
  12. 12.
    Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene. 2003;22(56):9087–96. doi:10.1038/sj.onc.1207231.PubMedCrossRefGoogle Scholar
  14. 14.
    Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drug. 2010;15(3):355–73. doi:10.1517/14728214.2010.497754.CrossRefGoogle Scholar
  15. 15.
    Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clinical cancer research: an official journal of the American Association for. Cancer Res. 2005;11(17):6333–41. doi:10.1158/1078-0432.CCR-05-0148.Google Scholar
  16. 16.
    Gao LF, Wen LJ, Yu H, Zhang L, Meng Y, Shao YT, Xu DQ, Zhao XJ. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol Sin. 2006;27(3):347–52. doi:10.1111/j.1745-7254.2006.00277.x.PubMedCrossRefGoogle Scholar
  17. 17.
    Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579–84.PubMedGoogle Scholar
  18. 18.
    Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clinical Investigation 1998;102(7):1385–92. doi:10.1172/JCI3785.CrossRefGoogle Scholar
  19. 19.
    Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U. S Am. 2000;97(8):4227–32.CrossRefGoogle Scholar
  20. 20.
    Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 1995;14(12):2857–65.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487–97. doi:10.1016/j.ccr.2009.10.015.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362 (9392):1255–60. doi:10.1016/S0140-6736(03)14567-9.PubMedCrossRefGoogle Scholar
  23. 23.
    Huang C, Jiang T, Zhu L, Liu J, Cao J, Huang KJ, Qiu ZJ. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int J Oncol. 2011;38(6):1637–44. doi:10.3892/ijo.2011.1000.PubMedGoogle Scholar
  24. 24.
    Huang Y, Qiu J, Dong S, Redell MS, Poli V, Mancini MA, Tweardy DJ. Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem. 2007;282(48):34958–67. doi:10.1074/jbc.M704548200.PubMedCrossRefGoogle Scholar
  25. 25.
    Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13(2):211–7.PubMedCrossRefGoogle Scholar
  26. 26.
    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. doi:10.1038/nature03546.PubMedCrossRefGoogle Scholar
  27. 27.
    Jing N, Li Y, Xu X, Sha W, Li P, Feng L, Tweardy DJ. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA cell Biol. 2003;22(11):685–96. doi:10.1089/104454903770946665.PubMedCrossRefGoogle Scholar
  28. 28.
    Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther. 2006;5(2):279–86. doi:10.1158/1535-7163.MCT-05-0302.PubMedCrossRefGoogle Scholar
  29. 29.
    Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell growth & differentiation: the molecular biology journal of the American Association for. Cancer Res. 2002;13(8):355–62.Google Scholar
  30. 30.
    Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Ca Res. 2009;15(11):3740–50. doi:10.1158/1078-0432.CCR-08-3252.Google Scholar
  31. 31.
    Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC cancer. 2003;3:23. doi:10.1186/1471-2407-3-23.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Ca Res. 2008;14(23):7682–90. doi:10.1158/1078-0432.CCR-08-1328.Google Scholar
  33. 33.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New Engl J Med. 2005;352(17):1779–90. doi:10.1056/NEJMoa051113.PubMedCrossRefGoogle Scholar
  34. 34.
    Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol. 2009;34(5):1209–20PubMedCentralPubMedGoogle Scholar
  35. 35.
    Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat. 2010;13(3):67–78. doi:10.1016/j.drup.2010.04.001.PubMedCrossRefGoogle Scholar
  36. 36.
    Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006;6(3):231–41. doi:10.1517/14712598.6.3.231.PubMedCrossRefGoogle Scholar
  37. 37.
    Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE, Grandis JR. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene. 2002;21(18):2846–53. doi:10.1038/sj.onc.1205385.PubMedCrossRefGoogle Scholar
  38. 38.
    Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. (2003) Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S Am. 2003;100(7):4138–43. doi:10.1073/pnas.0534764100.CrossRefGoogle Scholar
  39. 39.
    Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190–8. doi:10.1182/blood-2008-03-077966.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. doi:10.1016/j.ccr.2005.03.023.PubMedCrossRefGoogle Scholar
  41. 41.
    Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18(11):545–1. doi:10.1016/j.tcb.2008.08.008.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Liang Z, Gao LH, Cao LJ, Feng DY, Cao Y, Luo QZ, Yu P, Li M. Detection of STAT2 in early stage of cervical premalignancy and in cervical cancer. Asian Pac J Trop Med. 2012;5(9):738–42. doi:10.1016/S1995-7645(12)60117-5.PubMedCrossRefGoogle Scholar
  43. 43.
    Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst. 2006;2(11):536–50. doi:10.1039/b606246f.PubMedCrossRefGoogle Scholar
  44. 44.
    Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol. 2007;71(5):1435–43. doi:10.1124/mol.106.032284.PubMedCrossRefGoogle Scholar
  45. 45.
    Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62(12):3351–5.PubMedGoogle Scholar
  46. 46.
    Mertens C, Darnell JE Jr. SnapShot: JAK-STAT signaling. Cell. 2007;131(3):612. doi:10.1016/j.cell.2007.10.033.PubMedCrossRefGoogle Scholar
  47. 47.
    Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res: MCR. 2004;2(3):170–82.PubMedGoogle Scholar
  48. 48.
    Nagpal JK, Mishra R, Das BR. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer. 2002;94(9):2393–400. doi:10.1002/cncr.10499.PubMedCrossRefGoogle Scholar
  49. 49.
    Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15(14):3651–8.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Qian WF, Guan WX, Gao Y, Tan JF, Qiao ZM, Huang H, Xia CL. Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma. Braz J Med Biol Res. 2011;44(12):1222–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 2005;25(4):2761–5.PubMedGoogle Scholar
  52. 52.
    Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009;63(6):983–95. doi:10.1007/s00280-008-0823-6.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clinical cancer research: an official journal of the American Association for. Cancer Res. 2012a;18(18):4986–96. doi:10.1158/1078-0432.CCR-12-0792.Google Scholar
  54. 54.
    Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discov. 2012b. doi:10.1158/2159-8290.CD-12-0191.Google Scholar
  55. 55.
    Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Ca Res. 2004;10(20):6847–54. doi:10.1158/1078-0432.CCR-04-0744.Google Scholar
  56. 56.
    Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003;63(11):2948–56.PubMedGoogle Scholar
  57. 57.
    Timofeeva OA, Gaponenko V, Lockett SJ, Tarasov SG, Jiang S, Michejda CJ, Perantoni AO, Tarasova NI. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biolo. 2007;2(12):799–809. doi:10.1021/cb700186x.CrossRefGoogle Scholar
  58. 58.
    Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276(48):45443–55. doi:10.1074/jbc.M107527200.PubMedCrossRefGoogle Scholar
  59. 59.
    Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004a;3(3):261–9.Google Scholar
  60. 60.
    Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther. 2004b;3(12):1533–42.Google Scholar
  61. 61.
    Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem. 2005;280(38):32979–88. doi:10.1074/jbc.M502694200.PubMedCrossRefGoogle Scholar
  62. 62.
    Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol. 2007;31(1):129–36.PubMedGoogle Scholar
  63. 63.
    Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate. 2008;68(13):1430–42. doi:10.1002/pros.20807.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clinical cancer research: an official journal of the American Association for. Cancer Res. 2002;8(10):3065–74.Google Scholar
  65. 65.
    Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 2003;63(20):6763–71.PubMedGoogle Scholar
  66. 66.
    Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005;24(6):970–9. doi:10.1038/sj.onc.1208316.PubMedCrossRefGoogle Scholar
  67. 67.
    Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006;98(3):181–9. doi:10.1093/jnci/djj020.PubMedCrossRefGoogle Scholar
  68. 68.
    Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res. 2008;18(4):443–51. doi:10.1038/cr.2008.41.PubMedCrossRefGoogle Scholar
  69. 69.
    Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 2005;65(3):939–47.PubMedGoogle Scholar
  70. 70.
    Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nature reviews. Cancer. 2004;4(2):97–105. doi:10.1038/nrc1275.PubMedGoogle Scholar
  71. 71.
    Zhang L, Zhao Z, Feng Z, Yin N, Lu G, Shan B. RNA interference-mediated silencing of Stat5 induces apoptosis and growth suppression of hepatocellular carcinoma cells. Neoplasma. 2012;59(3):302–9. doi:10.4149/neo_2012_039.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Departments of OtolaryngologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Departments of Pharmacology & Chemical Biology, Eye & Ear InstituteUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations